In addition, a meta-analysis that analysed the 5 studies for the comparison of WBRT plus EGFR-TKIs and EGFR-TKIs alone in Cerebral metastatic NSCLC patients has presented that EGFR-TKIs provides similar clinical outcomes compared with WBRT plus EGFR-TKIs [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.